Physician profile
Mark D Moglowsky
NPI 1679527485
$8,411.63
in general payments reported to CMS, 2019-2025
26 companies · $56.71 in 2025
The $56.71 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,018 · 2020: $784 · 2021: $1,738 · 2022: $2,040 · 2023: $1,758 · 2024: $16.51 · 2025: $56.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,831.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,158.59 | 2019-2023 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $1,840.92 | 2019-2023 | |
| Janssen Biotech, INC. | $1,389.08 | 2019-2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $574.73 | 2019-2023 | Entyvio |
| Qol Medical, LLC | $266.02 | 2019-2023 | Sucraid |
| Nestle Healthcare Nutrition INC. | $265.74 | 2020-2023 | |
| Ironwood Pharmaceuticals, INC | $263.84 | 2019-2023 | Linzess |
| Merck Sharp & Dohme LLC | $256.33 | 2019-2023 | Dificid |
| Allergan, INC. | $228.14 | 2019-2020 | |
| Gilead Sciences, INC. | $202.86 | 2020-2023 | |
| Intercept Pharmaceuticals, INC. | $153.92 | 2019-2023 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $140.18 | 2022-2023 | Dupixent |
| Ferring Pharmaceuticals INC. | $133.57 | 2019-2023 | Cimzia, Clenpiq |
| Redhill Biopharma INC. | $110.37 | 2020-2022 | |
| Ucb, INC. | $94.49 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $71.92 | 2023-2025 | Resolution 360 Ultra Clip, Exalt Model D |
| Genzyme Corporation | $65.56 | 2023 | |
| Intra-Sana Laboratories | $36.02 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Pfizer INC. | $33.36 | 2019-2021 | |
| Celgene Corporation | $28.54 | 2022 | |
| Evoke Pharma, INC. | $19.09 | 2023 | Gimoti |
| Alfasigma USA, INC. | $18.22 | 2020 | |
| Micro-Tech Endoscopy USA, INC. | $16.51 | 2024 | Eyemax |
| Astrazeneca Pharmaceuticals LP | $16.06 | 2019 | |
| Braintree Laboratories, INC. | $15.85 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Moglowsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.